Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86


Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma.

Tong AA, Hashem H, Eid S, Allen F, Kingsley D, Huang AY.

Oncoimmunology. 2017 Mar 16;6(4):e1303586. doi: 10.1080/2162402X.2017.1303586. eCollection 2017.


Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.

Jamitzky S, Krueger AC, Janneschuetz S, Piepke S, Kailayangiri S, Spurny C, Rossig C, Altvater B.

Pediatr Blood Cancer. 2015 Nov;62(11):1979-85. doi: 10.1002/pbc.25619. Epub 2015 Jul 1.


Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.

Ayello J, Hochberg J, Flower A, Chu Y, Baxi LV, Quish W, van de Ven C, Cairo MS.

Exp Hematol. 2017 Feb;46:38-47. doi: 10.1016/j.exphem.2016.10.003. Epub 2016 Oct 17.


Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells.

Mueller SK, Altvater B, Chen C, Kailayangiri S, Ahlmann M, Dirksen U, Juergens H, Rossig C.

Oncol Rep. 2013 Jun;29(6):2348-54. doi: 10.3892/or.2013.2350. Epub 2013 Mar 19.


A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma.

Wagner J, Pfannenstiel V, Waldmann A, Bergs JWJ, Brill B, Huenecke S, Klingebiel T, Rödel F, Buchholz CJ, Wels WS, Bader P, Ullrich E.

Front Immunol. 2017 Jun 12;8:676. doi: 10.3389/fimmu.2017.00676. eCollection 2017.


An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells.

Lieberman NAP, DeGolier K, Haberthur K, Chinn H, Moyes KW, Bouchlaka MN, Walker KL, Capitini CM, Crane CA.

Front Immunol. 2018 Feb 2;9:150. doi: 10.3389/fimmu.2018.00150. eCollection 2018.


Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.

Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ, Lee DA.

PLoS One. 2012;7(1):e30264. doi: 10.1371/journal.pone.0030264. Epub 2012 Jan 18.


Autologous Immune Enhancement Therapy for Cancer - Our experience since 2004.

Terunuma H.

J Stem Cells Regen Med. 2012 Nov 26;8(3):205-6. eCollection 2012.


Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma.

Granzin M, Stojanovic A, Miller M, Childs R, Huppert V, Cerwenka A.

Oncoimmunology. 2016 Aug 5;5(9):e1219007. eCollection 2016.


Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.

Granzin M, Wagner J, Köhl U, Cerwenka A, Huppert V, Ullrich E.

Front Immunol. 2017 Apr 26;8:458. doi: 10.3389/fimmu.2017.00458. eCollection 2017. Review.


Expansion, purification, and functional assessment of human peripheral blood NK cells.

Somanchi SS, Senyukov VV, Denman CJ, Lee DA.

J Vis Exp. 2011 Feb 2;(48). pii: 2540. doi: 10.3791/2540.


Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.

Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SM, Coustan-Smith E, Imai C, Campana D.

Blood. 2014 Aug 14;124(7):1081-8. doi: 10.1182/blood-2014-02-556837. Epub 2014 Jul 8.


Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer.

Mimura K, Kamiya T, Shiraishi K, Kua LF, Shabbir A, So J, Yong WP, Suzuki Y, Yoshimoto Y, Nakano T, Fujii H, Campana D, Kono K.

Int J Cancer. 2014 Sep 15;135(6):1390-8. doi: 10.1002/ijc.28780. Epub 2014 Feb 28.


CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.

Wennerberg E, Kremer V, Childs R, Lundqvist A.

Cancer Immunol Immunother. 2015 Feb;64(2):225-35. doi: 10.1007/s00262-014-1629-5. Epub 2014 Oct 26.


Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.

Ayello J, van de Ven C, Cairo E, Hochberg J, Baxi L, Satwani P, Cairo MS.

Exp Hematol. 2009 Oct;37(10):1216-29. doi: 10.1016/j.exphem.2009.07.009. Epub 2009 Jul 26.


A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.

Yang H, Tang R, Li J, Liu Y, Ye L, Shao D, Jin M, Huang Q, Shi J.

Cell Biochem Biophys. 2015 Dec;73(3):723-9. doi: 10.1007/s12013-015-0688-3.


Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.

Geller MA, Knorr DA, Hermanson DA, Pribyl L, Bendzick L, McCullar V, Miller JS, Kaufman DS.

Cytotherapy. 2013 Oct;15(10):1297-306. doi: 10.1016/j.jcyt.2013.05.022.


Multiple effects of IL-21 on human NK cells in ex vivo expansion.

Li Q, Ye LJ, Ren HL, Huyan T, Li J, Shi JL, Huang QS.

Immunobiology. 2015 Jul;220(7):876-88. doi: 10.1016/j.imbio.2015.01.009. Epub 2015 Jan 31.


Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy.

Granzin M, Soltenborn S, Müller S, Kollet J, Berg M, Cerwenka A, Childs RW, Huppert V.

Cytotherapy. 2015 May;17(5):621-32. doi: 10.1016/j.jcyt.2015.03.611.


Characterization and ex vivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy.

Kang L, Voskinarian-Berse V, Law E, Reddin T, Bhatia M, Hariri A, Ning Y, Dong D, Maguire T, Yarmush M, Hofgartner W, Abbot S, Zhang X, Hariri R.

Front Immunol. 2013 May 1;4:101. doi: 10.3389/fimmu.2013.00101. eCollection 2013.

Supplemental Content

Support Center